Atyr Pharma Inc (ATYR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -60,159 | -34,413 | -14,881 | -64,022 | -49,054 |
| Depreciation Amortization | -334 | -211 | -140 | -1,165 | -614 |
| Other Working Capital | 6,913 | 2,827 | -1,577 | -6,918 | -8,538 |
| Other Operating Activity | 3,790 | 2,483 | 1,178 | 2,986 | 2,219 |
| Operating Cash Flow | $-49,790 | $-29,314 | $-15,420 | $-69,119 | $-55,987 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -21,450 | -1,110 | -4,420 | 17,291 | 23,358 |
| PPE Investments | -46 | -9 | N/A | -58 | -40 |
| Investing Cash Flow | $-21,496 | $-1,119 | $-4,420 | $17,233 | $23,318 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -400 | -264 | -131 | -497 | -369 |
| Common Stock Issued | 66,542 | 36,789 | 18,759 | 40,361 | 21,394 |
| Financing Cash Flow | $66,142 | $36,525 | $18,628 | $39,864 | $21,025 |
| Beginning Cash Position | 14,006 | 14,006 | 14,006 | 26,028 | 26,028 |
| End Cash Position | 8,862 | 20,098 | 12,794 | 14,006 | 14,384 |
| Net Cash Flow | $-5,144 | $6,092 | $-1,212 | $-12,022 | $-11,644 |
| Free Cash Flow | |||||
| Operating Cash Flow | -49,790 | -29,314 | -15,420 | -69,119 | -55,987 |
| Capital Expenditure | -46 | -9 | N/A | -65 | -40 |
| Free Cash Flow | -49,836 | -29,323 | -15,420 | -69,184 | -56,027 |